ReviewWorld journal of urology2014
Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy.
Review in World journal of urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Immunotherapy for metastatic renal cell carcinoma.The Cochrane database of systematic reviews · 2017Pooled it
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Trial
- Upregulation ofTranslational andrology and urology · 2026Article
- Article
- [Adjuvant therapy for renal cell carcinoma : Relevant patient and tumor factors].Urologie (Heidelberg, Germany) · 2024Review
- Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future.Cancers · 2022Review
- Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review.Croatian medical journal · 2020Article
- Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer.Ochsner journal · 2019Review
- Circulating Tumor Cells for the Management of Renal Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2018Review
- Toxicity mechanism-based prodrugs: glutathione-dependent bioactivation as a strategy for anticancer prodrug design.Expert opinion on drug discovery · 2018Review
- Specific immunotherapy in renal cancer: a systematic review.Therapeutic advances in urology · 2017Review
- Systemic therapy in metastatic renal cell carcinoma.World journal of urology · 2017Review
- Tumour and patient factors in renal cell carcinoma-towards personalized therapy.Nature reviews. Urology · 2015Review
- Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma.Human vaccines & immunotherapeutics · 2015Review
- Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.Targeted oncology · 2014Review
- SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.Expert review of vaccines · 2014Review
- Polypoid Gallbladder Lesion in the Context of Renal Cell Carcinoma: Is Laparoscopic Cholecystectomy a Reasonable Option?Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-specific immunotherapy has been for a long time a standard treatment option for patients with metastatic renal cell carcinoma but was redeemed by specific targeted molecular therapies, namely the VEGF and mTOR inhibitors. After moving treatment for mRCC to specific molecular agents with a well-defined mode of action, immunotherapy still needs this further development to increase its accuracy. Nowadays, an evolution from a rather non-specific cytokine treatment to sophisticated targeted approaches in specific immunotherapy led to a re-launch of immunotherapy in clinical studies. Recent steps in the development of immunotherapy strategies are discussed in this review with a special focus on peptide vaccination which aims at a tumor targeting by specific T lymphocytes. In addition, different combinatory strategies with immunomodulating agents like cyclophosphamide or sunitinib are outlined, and the effects of immune checkpoint modulators as anti-CTLA-4 or PD-1 antibodies are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.